<p>According to the Muscular Dystrophy Association, myasthenia gravis is an autoimmune disorder in which the immune system attacks the body's tissues, disrupting the communication between nerves and muscles at the neuromuscular junction. The primary target of the pathogenic autoantibodies in myasthenia gravis is the nicotinic acetylcholine receptor (AChR), followed by muscle-specific kinase (MuSK) and lipoprotein receptor-related protein 4 (LRP4). This condition presents with painless, fluctuating muscle weakness, which worsens with activity. The most common initial signs are ocular weakness, leading to asymmetric ptosis (drooping eyelids) and binocular diplopia (double vision), although in rarer cases, the first signs may be isolated oropharyngeal (throat) or limb weakness.</p>
<h2><strong>Myasthenia Gravis Epidemiological Segmentation</strong></h2>
<p>The Epidemiological Segmentation of Myasthenia Gravis in 7MM from 2020 to 2034 is segmented as:-</p>
<ul>
<li>Total Diagnosed Prevalent Cases of Myasthenia Gravis</li>
<li>Gender-specific Diagnosed Prevalent cases of Myasthenia Gravis</li>
<li>Age-specific Diagnosed Prevalent cases of Myasthenia Gravis</li>
<li>Diagnosed Prevalent Cases of Myasthenia Gravis by MGFA classification</li>
<li>Diagnosed Prevalent Cases of Generalized Myasthenia Gravis by Antibody Serology in the 7MM</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/myasthenia-gravis-epidemiology-forecast"><span style="text-decoration: underline;"><strong>Myasthenia Gravis Epidemiology</strong></span></a></h2>
<ul>
<li>In 2023, approximately 129K individuals in the US were diagnosed with myasthenia gravis, with the number expected to rise at a CAGR throughout the 2020-2034 period.</li>
<li>EU4 and the UK collectively accounted for around 125K diagnosed cases of myasthenia gravis, with cases projected to increase during the forecast period (2023-2034).</li>
<li>Germany reported the highest diagnosed cases of myasthenia gravis in EU4 and the UK, with 39K cases, followed by the UK and France, while Spain had the lowest number.</li>
<li>Japan had around 32K diagnosed cases of myasthenia gravis in 2023, with cases expected to grow at a significant CAGR.</li>
<li>The highest proportion of cases was found in individuals aged 65 and above, while the lowest was in the 0-17 age group across the 7MM.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/myasthenia-gravis-market"><span style="text-decoration: underline;"><strong>Myasthenia Gravis Market</strong></span></a></h2>
<p>The Myasthenia Gravis market size in the 7MM was ~USD5 Billion in 2023.</p>
<h2>Myasthenia Gravis Market Drivers:</h2>
<ul>
<li>The rising prevalence of myasthenia gravis (MG) and the increasing geriatric population provide a steady demand for treatments and therapies.</li>
<li>As the market expands, more companies are entering the myasthenia gravis treatment space, boosting competition and driving innovation.</li>
</ul>
<h2>Myasthenia Gravis Market Barriers:</h2>
<ul>
<li>Limited treatment options and a lack of effective therapies for certain MG subtypes may hinder market growth.</li>
<li>The high cost of emerging treatments, including biologics and advanced therapies, could limit patient access and adoption.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/myasthenia-gravis-pipeline-insight"><span style="text-decoration: underline;"><strong>Myasthenia Gravis Emerging Drugs</strong></span></a></h2>
<ul>
<li>UPLIZNA</li>
<li>Nipocalimab</li>
<li>ENSPRYNG&nbsp;</li>
<li>Batoclimab</li>
<li>Gefurulimab&nbsp;</li>
<li>Pozelimab + Cemdisiran</li>
<li>KYV-101</li>
</ul>
<p>And others.&nbsp;</p>
<h2><strong>Myasthenia Gravis Key Players</strong></h2>
<ul>
<li>Horizon Therapeutics</li>
<li>Amgen</li>
<li>Janssen Research &amp; Development, LLC</li>
<li>Hoffmann-La Roche</li>
<li>Immunovant Sciences GmbH</li>
<li>Alexion, AstraZeneca Rare Disease</li>
<li>Regeneron Pharmaceuticals</li>
<li>Kyverna Therapeutics</li>
<li>Cartesian Therapeutics</li>
<li>Dianthus Therapeutics</li>
<li>Takeda</li>
<li>COUR Pharmaceuticals</li>
</ul>
<p>And others.</p>

Myasthenia Gravis Market Infographic

Myasthenia Gravis Market Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.